Neuroscience

How Wearable Devices and Digital Clinical Measures Can Improve Neurology Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 15, 2021
Actigraphy, University, Drug development, Center, Department of Neurology, Xuanwu hospital, University Medical Center, Patient, University of Rochester, Digital, University Medical Center Utrecht, Assistant, Industry, Food, Department, Assistant professor, Research, Neuroscience, Pharmaceutical industry, Medical imaging

Digital clinical measures enabled by wearables have great potential to transform and accelerate drug development in neuroscience.

Key Points: 
  • Digital clinical measures enabled by wearables have great potential to transform and accelerate drug development in neuroscience.
  • Digital assessments of function, as quantified from smart sensor data, can provide frequent, objective and precise measures of how patients function in their real lives.
  • In particular, wearable devices collect continuous digital data remotely and passively, thus improving patient-centricity and reducing trial burden on patients.
  • For more information, or to register for this event, visit How Wearable Devices and Digital Clinical Measures Can Improve Neurology Trials.

ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

Retrieved on: 
Wednesday, September 15, 2021
Amyotrophic lateral sclerosis, AD, Disease, Toronto Stock Exchange, Parkinson's disease, PD, EST, Alzheimer's disease, Conference, Protein, Company, PMN, Intention, Neuroscience, Epitope, Therapy, Neurodegeneration, GLOBE, PROMIS, ALS, TSX, Pharmaceutical industry, Vaccine

ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting her talk entitled Selective Targeting of Misfolded Pathogenic Proteins in Neurodegenerative Diseases on Sept.16 at 12:40 PM, EST in the session "The Next Undruggable Leaders".

Key Points: 
  • ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting her talk entitled Selective Targeting of Misfolded Pathogenic Proteins in Neurodegenerative Diseases on Sept.16 at 12:40 PM, EST in the session "The Next Undruggable Leaders".
  • Registered attendees can view the presentation live during the Conference; a recorded version for attendees will also be available to watch at their convenience.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The Neuroscience of Effective Teams: Sounding Board Teams Up with Leading Psychologists for Upcoming Webinar

Retrieved on: 
Wednesday, September 15, 2021
Associate, ATD, Economics, GOLD, Neuroscience, Organization, Motivation, Research, Efficiency, Sounding board, State Department Sounding Board, Digital learning, Management

Effective teams are the foundation of every successful organization, recognized for driving innovation, productivity and efficiency.

Key Points: 
  • Effective teams are the foundation of every successful organization, recognized for driving innovation, productivity and efficiency.
  • On the flip side, dysfunctional teams are characterized by conflict and a lack of engagement, often negatively impacting business outcomes and the bottom line.
  • Understanding the neuroscience behind teams can help organizations overcome common challenges, including those created by the recent shift to a more hybrid, remote workforce.
  • Drawing on their research, the panelists will explore the dynamics of effective teams from a social neuroscience perspective, focusing on motivation, cooperation and decision-making.

Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Prevalence, Trial of the century, Caregiver burden, Biomarker, Biotechnology, Mutation, Microglia, Immune system, Genetic testing, Neurodegeneration, Neuroscience, TREM2, Patient, Institute, Disease, Physician, Physical, Autosome, Lists of diseases, Diagnosis, Life, Life expectancy, University College London, Pharmaceutical industry, Medical imaging, VGL101, ALSP, Vigil Neuroscience, VGL101, ALSP, VIGIL NEUROSCIENCE

Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Key Points: 
  • Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
  • ALSP is a rare, genetically defined fatal neurodegenerative disease with strong mechanistic and biochemical associations to microglia dysfunction.
  • This study is a key component in the development plan of our lead clinical candidate, VGL101, as a potential treatment option for ALSP patients.
  • Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, inherited, autosomal dominant neurological disease with high penetrance.

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

*CORRECTION* IncludeHealth Launches “MSK Operating System” in Collaboration with Google and ProMedica Health System

Retrieved on: 
Wednesday, September 15, 2021
MSK, HIPAA, TensorFlow, Government, Patient, Human musculoskeletal system, ProMedica, CEO, Computer, Efficiency, Technology, Occupational therapy, Solution, MD, Tablet, Attorney General Wells, GLOBE, Google, Motion, Time, Neuroscience, Founder CEO, Pharmaceutical industry, Medicine

CINCINNATI, OHIO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- IncludeHealth , a digital musculoskeletal (MSK) health company, today launched its proprietary Musculoskeletal Operating System (MSK-OS) in collaboration with Google and ProMedica Health System.

Key Points: 
  • CINCINNATI, OHIO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- IncludeHealth , a digital musculoskeletal (MSK) health company, today launched its proprietary Musculoskeletal Operating System (MSK-OS) in collaboration with Google and ProMedica Health System.
  • First previewed at the 2021 Google I/O conference , the innovation significantly advances the speed and applicability of traditional pose estimation models for virtual MSK care.
  • ProMedica Health System, an integrated healthcare system headquartered in Toledo, Ohio serving communities in 28 states, has partnered with IncludeHealth to offer this breakthrough platform to its patients.
  • IncludeHealth is a digital musculoskeletal health company delivering next-generation musculoskeletal care.

Vivera Pharmaceuticals Joins Forces with DoctorsOne Healthcare Systems and Manny Pacquiao Foundation for Vaccine Campaign in Underserved SoCal Communities

Retrieved on: 
Tuesday, September 14, 2021
Cruiserweight (boxing), CEO, Vaccination, FDA, Health, Neuroscience, Patient, Company, Safety, MPF, Solution, COVID-19, Partnership, Hope, Population, Prevalence, Awareness, Pharmaceutical industry, Vaccine

NEWPORT BEACH, Calif., Sept. 14, 2021 /PRNewswire/ --Vivera Pharmaceuticals, Inc., in partnership with DoctorsOne Healthcare Systems (Doc1 Health) and the Manny Pacquiao Foundation, announced the launch of a joint vaccination initiative in Southern California.

Key Points: 
  • NEWPORT BEACH, Calif., Sept. 14, 2021 /PRNewswire/ --Vivera Pharmaceuticals, Inc., in partnership with DoctorsOne Healthcare Systems (Doc1 Health) and the Manny Pacquiao Foundation, announced the launch of a joint vaccination initiative in Southern California.
  • By bringing together each teams' respective expertise, the initiative strives to increase awareness for the low vaccination rates among underserved communities of Los Angeles County.
  • The partnership between Vivera and Doc1 Health will lead to various awareness campaigns and vaccination events in several Southern California communities.
  • The Manny Pacquiao Foundation, founded by Manny Pacquiao, aneight-division World Boxing Champion, and current Philippine Senator, is spearheading community outreach efforts for the campaign.

Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

Retrieved on: 
Tuesday, September 14, 2021
Survivor, MSK, Program, Food, Therapy, SAN, NCCN, Quality of life, CEO, FDA, University, Caregiver, Depression, Doctor of Philosophy, Patient, Fear, Anxiety, Software, National Comprehensive Cancer Network, Blue Note Records, PDT, Food and Drug Administration, Safety, Partnership, Recurrence, Massachusetts General Hospital, Cancer, Neuroscience, Memorial Sloan Kettering Cancer Center, Innovation Hub, Pharmaceutical industry, Medicine

SAN FRANCISCO, Sept. 14, 2021 /PRNewswire/ --Blue Note Therapeutics, a prescription digital therapeutics company singularly dedicated to serving patients experiencing cancer, today announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) to help advance the development of the company's prescription digital therapeutic (PDT) candidate to treat fear of cancer recurrence.

Key Points: 
  • SAN FRANCISCO, Sept. 14, 2021 /PRNewswire/ --Blue Note Therapeutics, a prescription digital therapeutics company singularly dedicated to serving patients experiencing cancer, today announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) to help advance the development of the company's prescription digital therapeutic (PDT) candidate to treat fear of cancer recurrence.
  • "We are excited for this opportunity to further our partnership with MSK," said Geoffrey Eich, CEO of Blue Note Therapeutics.
  • "This new collaboration will give Blue Note access to leading cancer experts to advise and inform the development of our therapeutic, increasing our capacity to reach patients."
  • Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to serving patients suffering from cancer.

Cortical.io Secures Another $6 Million Series A Investment

Retrieved on: 
Tuesday, September 14, 2021
Artificial intelligence, Acceleration, SAN, AI, Technology, Natural language, Classification, Consultant, IDP, Marketing, Attention, European Investment Bank, COO, Solution, Growth, NLU, Contract, Google, EIB, Neuroscience, Information technology, Internet service provider

VIENNA and SAN FRANCISCO, Sept. 14, 2021 /PRNewswire-PRWeb/ -- Cortical.io today announced a $6 million series A investment into the company.

Key Points: 
  • VIENNA and SAN FRANCISCO, Sept. 14, 2021 /PRNewswire-PRWeb/ -- Cortical.io today announced a $6 million series A investment into the company.
  • The investment was provided by Ezpada, a global commodity trading house.
  • It's a complicated problem that tech giants like Google and Amazon have invested massive dollars in developing natural language technology.
  • Earlier this year, the European Investment Bank (EIB) provided $9.1 million to Cortical.io.